Authors' reply

The Lancet

Volumn 381, Issue 9872, 2013, Pages 1094-1095

  Sabchareon, Arunee ^a   Wallace, Derek ^b   Lang, Jean ^c   Bouckenooghe, Alain ^b   Moureau, Annick ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Sanofi Pasteur Clinical Development Department   (Singapore)

^c SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE;

BLOOD SAMPLING; DEMOGRAPHY; DENGUE VIRUS; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; DENGUE; FEMALE; MALE; NOTE;

DENGUE; DENGUE VACCINES; FEMALE; HUMANS; MALE;

EID: 84875725647     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60755-2     Document Type: Letter

References (3)

1. A Sabchareon, D Wallace, C Sirivichayakul et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial Lancet 380 2012 1559 1567
2. RZ Capeding, IA Luna, E Bomasang et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines Vaccine 29 2011 3863 3872
3. NH Tran, TKT Nguyen, R Forrat, M Saville, A Bouckenooghe, A Wartel-Tram Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children J Vaccines Vaccin 3 2012 162